Skip to content
Tenfell
Awarded contract
Published 04 Nov 2022

NHS National Pharmaceuticals Transition 2022_2

NHS England · London

Key facts

Awarded
01 Nov 2022
Contract starts
01 Dec 2022
Contract ends
31 May 2024
Procedure
Open procedure (above threshold)
Buyer type
Central government

Awarded to 18 suppliers

SupplierValue
Takeda UK Limited—
Colonis Pharma Ltd—
Dr Reddy's Laboratories (UK) Ltd—
Gerot Lannach UK Ltd—
Pfizer Ltd—
Teva UK Ltd—
Selective Supplies Ltd—
Thornton & Ross Ltd—
Wockhardt UK Limited—
Accord-UK Ltd—
Mylan—
Amarox Limited—
Milpharm Ltd/aurobinbdo—
Cipla Limited—
Glenmark Pharmaceuticals Europe Ltd—
Aspire Pharma Ltd—
Ascend Laboratories UK Ltd—
Morningside Pharmaeuticals—

Description

Invitation to offer for NHS National Pharmaceuticals Transition 2022_2 Offer reference number: CM/PHG/22/5655 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months. Potential periods of call-offs under the framework agreement: Transition: CESW: 01/12/2022 to 30/09/2023 (10 months) LSNE: 01/12/2022 to 31/05/2024 (18 months) NWLN: 01/12/2022 to 31/05/2023 (6 months)

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.